flucytosine has been researched along with AIDS-Related Opportunistic Infections in 89 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of this study have demonstrated that both fluconazole and flucytosine are safe and well tolerated in the treatment of esophageal candidiasis in AIDS patients." | 9.08 | Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. ( Barbarini, G; Barbaro, G; Di Lorenzo, G, 1995) |
| "The results of this study have demonstrated that both fluconazole and itraconazole+flucytosine association are efficacious in short-term treatment of esophageal candidiasis in AIDS patients with a statistically significant difference in comparison to placebo." | 9.08 | Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group. ( Barbarini, G; Barbaro, G; Di Lorenzo, G, 1996) |
| "Treatment with fluconazole, 200 mg/day, was introduced." | 5.29 | [Clinical fluconazole and itraconazole resistance of oro-gastrointestinal candidiasis in a patient with AIDS]. ( Boyvat, A; Geilen, CC; Orfanos, CE; Seibold, M; Tebbe, B; Wölfer, LU, 1996) |
| "The results of this study have demonstrated that both fluconazole and flucytosine are safe and well tolerated in the treatment of esophageal candidiasis in AIDS patients." | 5.08 | Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. ( Barbarini, G; Barbaro, G; Di Lorenzo, G, 1995) |
| "The results of this study have demonstrated that both fluconazole and itraconazole+flucytosine association are efficacious in short-term treatment of esophageal candidiasis in AIDS patients with a statistically significant difference in comparison to placebo." | 5.08 | Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group. ( Barbarini, G; Barbaro, G; Di Lorenzo, G, 1996) |
| " While amphotericin B, usually in combination with flucytosine, generally is recommended as primary therapy for patients with severe forms of disease, especially cryptococcal meningitis, alternative treatment regimens have been developed or are under investigation." | 4.78 | Management of cryptococcosis. ( Dismukes, WE, 1993) |
| "Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa." | 3.11 | Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. ( Boulware, DR; Boyer-Chammard, T; Chawinga, C; Chen, T; Comins, K; Harrison, TS; Hlupeni, A; Hope, W; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Jjunju, S; Kagimu, E; Kanyama, C; Kasibante, J; Lalloo, DG; Lawrence, DS; Leeme, T; Lortholary, O; Loyse, A; Meintjes, G; Meya, DB; Molloy, SF; Mosepele, M; Moyo, M; Mpoza, E; Mutata, C; Muzoora, C; Mwandumba, HC; Mzinganjira, H; Ndhlovu, CE; Nuwagira, E; Rhein, J; Rutakingirwa, MK; Schutz, C; Siamisang, K; Singh, A; Ssebambulidde, K; Tugume, L; van Widenfelt, E; Wang, D; Youssouf, N, 2022) |
| "Mortality related to cryptococcal meningitis remains high, and novel treatment strategies are needed." | 2.77 | Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. ( Bekker, LG; Bicanic, T; Harrison, TS; Jarvis, JN; Meintjes, G; Rebe, K; Schutz, C; Williams, A; Williams, GN; Wood, R, 2012) |
| " Fluconazole at a dosage of 1200 mg per day is more fungicidal than at a dosage of 800 mg per day, but mortality rates remain unacceptably high." | 2.75 | Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. ( Harrison, TS; Hosseinipour, MC; Jackson, A; Jaffar, S; Jarvis, JN; Kamwendo, D; Kanyemba, C; Kenala, J; Namarika, D; Nussbaum, JC; Phulusa, J; van der Horst, CM, 2010) |
| " We conducted a prospective phase II dose escalation study employing doses of fluconazole ranging from 800 to 2000 mg daily for 10 weeks used alone or combined with flucytosine at 100 mg/kg per day for the first 4 weeks." | 2.73 | Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. ( Bozzette, SA; Haubrich, R; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Milefchik, E; Tilles, JG, 2008) |
| " A dosage range for AmB of 0." | 2.73 | High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. ( Bekker, LG; Bicanic, T; Brouwer, A; Harrison, T; Jaffar, S; Loyse, A; Meintjes, G; Rebe, K; Wood, R, 2008) |
| "Treatment of cryptococcal meningitis with amphotericin B or fluconazole is often unsuccessful; in only 35%-40% of cases do CSF cultures become negative by 10 weeks after initiation of such therapy." | 2.67 | Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. ( Bauer, M; Bozzette, SA; Forthal, D; Haghighat, D; Jones, BE; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Tilles, JG, 1994) |
| "Mortality from HIV-associated cryptococcal meningitis remains high (10-30%), even in developed countries, because of the inadequacy of current antifungal drugs and the complication of raised intracranial pressure." | 2.42 | Cryptococcal meningitis. ( Bicanic, T; Harrison, TS, 2004) |
| "neoformans was noted for patients with cryptococcal meningitis whose computed tomographic scans appeared normal on presentation." | 2.39 | Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. ( Allworth, AM; Gottlieb, T; Heath, CH; McGregor, AR; Mitchell, DH; Papanaoum, K; Richards, MJ; Sorrell, TC, 1995) |
| "In the U." | 2.38 | Cryptococcal meningitis in patients with AIDS. ( Mocsny, N, 1992) |
| "Cryptococcal prostatitis is a rare disease that unusually presents in immunodeficient patients." | 1.51 | An AIDS patient with urine retention. ( Cheng, J; Tao, R; Xu, L; Zhao, Q; Zhu, B, 2019) |
| "A diagnosis of cryptococcal meningitis was made and the patient was started on 1200 mg fluconazole once daily and flucytosine 25 mg/kg four times daily as part of the Advancing Cryptococcal Treatment for Africa (ACTA) clinical trial." | 1.48 | Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report. ( Benjamin, LA; Ellis, JP; Harrison, TS; Heyderman, RS; Joekes, EC; Kalata, N; Kampondeni, S; Lalloo, DG, 2018) |
| "In the United States, cryptococcal meningitis causes approximately 3400 hospitalizations and approximately 330 deaths annually." | 1.43 | Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. ( Boulware, DR; Merry, M, 2016) |
| "3), and the rate of attributable mortality among those not receiving the recommended dose of initial therapy was higher than that of those receiving recommended dosing (HR, 2." | 1.39 | Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. ( Bratton, EW; Chastain, CA; El Husseini, N; Juliano, JJ; Lee, MS; Perfect, JR; Poole, C; Stürmer, T; Weber, DJ, 2013) |
| "Cryptococcosis is a life-threatening opportunistic fungal infection in both HIV-positive and -negative patients." | 1.34 | Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. ( Dromer, F; Launay, O; Lortholary, O; Mathoulin-Pélissier, S, 2007) |
| "Two patients with HIV/AIDS (CD4 counts of 8 and 81 cells/mm(3)) presented with altered mental status, visual changes, florid cryptococcal meningitis, and elevated ICP (>500 mm CSF) without evidence of hydrocephalus on computed tomography scan." | 1.33 | The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis. ( McGirt, MJ; Rigamonti, D; Williams, MA; Woodworth, GF, 2005) |
| "The resolution of this Acanthamoeba infection was secondary to a multidisciplinary treatment approach involving a combination of surgery as well as high-dose amphotericin B plus 5-fluorocytosine." | 1.33 | Successful treatment of Acanthamoeba rhinosinusitis in a patient with AIDS. ( Nachega, JB; Rombaux, P; Thomas, G; Weynand, B; Zech, F, 2005) |
| "Treatment with amphotericin B and flucytosine was instituted in both the children who recovered and are doing well." | 1.32 | Cryptococcal meningitis in pediatric AIDS. ( Kakkar, M; Kaur, R; Monga, R; Rawat, D; Sharma, VK, 2003) |
| "laurentii meningitis was controlled after 2 weeks of treatment with no evidence of infection 20 months later." | 1.30 | First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. ( Avlami, A; Georgakopoulos, G; Kordossis, T; Legakis, NJ; Papalambrou, C; Stefanou, I; Velegraki, A, 1998) |
| "Flucytosine resistance was seen in only 12 (3." | 1.29 | High prevalence of antifungal resistance in Candida spp. from patients with AIDS. ( Denning, DW; Ganguli, LA; Keaney, MG; Law, D; Moore, CB; Wardle, HM, 1994) |
| "We report a case of cryptococcal meningitis in a 31-year-old HIV-positive man which was successfully treated with amphotericin B lipid emulsion." | 1.29 | Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B. ( Appleyard, MN; Hartley, JP; Leake, HA, 1994) |
| "Treatment with fluconazole, 200 mg/day, was introduced." | 1.29 | [Clinical fluconazole and itraconazole resistance of oro-gastrointestinal candidiasis in a patient with AIDS]. ( Boyvat, A; Geilen, CC; Orfanos, CE; Seibold, M; Tebbe, B; Wölfer, LU, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 41 (46.07) | 18.2507 |
| 2000's | 26 (29.21) | 29.6817 |
| 2010's | 18 (20.22) | 24.3611 |
| 2020's | 4 (4.49) | 2.80 |
| Authors | Studies |
|---|---|
| Jarvis, JN | 5 |
| Lawrence, DS | 1 |
| Meya, DB | 1 |
| Kagimu, E | 1 |
| Kasibante, J | 1 |
| Mpoza, E | 1 |
| Rutakingirwa, MK | 1 |
| Ssebambulidde, K | 1 |
| Tugume, L | 1 |
| Rhein, J | 1 |
| Boulware, DR | 3 |
| Mwandumba, HC | 1 |
| Moyo, M | 1 |
| Mzinganjira, H | 1 |
| Kanyama, C | 2 |
| Hosseinipour, MC | 4 |
| Chawinga, C | 2 |
| Meintjes, G | 5 |
| Schutz, C | 2 |
| Comins, K | 1 |
| Singh, A | 1 |
| Muzoora, C | 1 |
| Jjunju, S | 1 |
| Nuwagira, E | 1 |
| Mosepele, M | 1 |
| Leeme, T | 1 |
| Siamisang, K | 1 |
| Ndhlovu, CE | 1 |
| Hlupeni, A | 1 |
| Mutata, C | 1 |
| van Widenfelt, E | 1 |
| Chen, T | 2 |
| Wang, D | 2 |
| Hope, W | 1 |
| Boyer-Chammard, T | 1 |
| Loyse, A | 5 |
| Molloy, SF | 2 |
| Youssouf, N | 1 |
| Lortholary, O | 6 |
| Lalloo, DG | 3 |
| Jaffar, S | 5 |
| Harrison, TS | 12 |
| Temfack, E | 2 |
| Xu, L | 1 |
| Tao, R | 1 |
| Zhao, Q | 1 |
| Cheng, J | 1 |
| Zhu, B | 1 |
| Shroufi, A | 1 |
| Chiller, T | 1 |
| Jordan, A | 1 |
| Denning, DW | 3 |
| Govender, NP | 2 |
| Baptiste, S | 1 |
| Rajasingham, R | 1 |
| Ribeiro, I | 1 |
| Van Cutsem, G | 1 |
| Chen, CH | 1 |
| Li, H | 1 |
| Chen, HM | 1 |
| Chen, YM | 1 |
| Chang, YJ | 1 |
| Lin, PY | 1 |
| Hsu, CW | 1 |
| Tseng, PT | 1 |
| Lin, KH | 1 |
| Tu, YK | 1 |
| Wirth, F | 1 |
| de Azevedo, MI | 1 |
| Pilla, C | 1 |
| Aquino, VR | 1 |
| Neto, GW | 1 |
| Goldani, LZ | 1 |
| Heyderman, RS | 2 |
| Kouanfack, C | 1 |
| Chanda, D | 1 |
| Mfinanga, S | 1 |
| Lakhi, S | 1 |
| Lesikari, S | 1 |
| Chan, AK | 1 |
| Stone, N | 1 |
| Kalata, N | 2 |
| Karunaharan, N | 1 |
| Gaskell, K | 1 |
| Peirse, M | 1 |
| Ellis, J | 1 |
| Lontsi, S | 1 |
| Ndong, JG | 1 |
| Bright, P | 1 |
| Lupiya, D | 1 |
| Bradley, J | 1 |
| Adams, J | 1 |
| van der Horst, C | 3 |
| van Oosterhout, JJ | 1 |
| Sini, V | 1 |
| Mapoure, YN | 1 |
| Mwaba, P | 1 |
| Bicanic, T | 6 |
| Ellis, JP | 1 |
| Joekes, EC | 1 |
| Kampondeni, S | 1 |
| Benjamin, LA | 1 |
| Bratton, EW | 1 |
| El Husseini, N | 1 |
| Chastain, CA | 1 |
| Lee, MS | 1 |
| Poole, C | 1 |
| Stürmer, T | 1 |
| Weber, DJ | 1 |
| Juliano, JJ | 1 |
| Perfect, JR | 1 |
| Trpković, A | 1 |
| Pekmezović, M | 1 |
| Barać, A | 1 |
| Crnčević Radović, L | 1 |
| Arsić Arsenijević, V | 1 |
| Dromer, F | 4 |
| Day, J | 1 |
| Mahabeer, Y | 1 |
| Chang, CC | 1 |
| Naidu, D | 1 |
| Dorasamy, A | 1 |
| Lewin, S | 1 |
| Ndung'u, T | 1 |
| Moosa, MY | 1 |
| French, M | 1 |
| Mlisana, K | 1 |
| Coovadia, Y | 1 |
| Banoo, S | 1 |
| Córdoba, S | 1 |
| Isla, MG | 1 |
| Szusz, W | 1 |
| Vivot, W | 1 |
| Altamirano, R | 1 |
| Davel, G | 1 |
| Merry, M | 1 |
| Nussbaum, JC | 2 |
| Jackson, A | 1 |
| Namarika, D | 2 |
| Phulusa, J | 2 |
| Kenala, J | 1 |
| Kanyemba, C | 2 |
| Kamwendo, D | 1 |
| van der Horst, CM | 2 |
| Nweze, EI | 1 |
| Ogbonnaya, UL | 1 |
| Rebe, K | 2 |
| Williams, GN | 1 |
| Williams, A | 1 |
| Bekker, LG | 3 |
| Wood, R | 3 |
| Milani, B | 1 |
| Ford, N | 1 |
| Jackson, AT | 1 |
| Chikasema, M | 1 |
| Liao, CH | 1 |
| Chi, CY | 1 |
| Wang, YJ | 1 |
| Tseng, SW | 1 |
| Chou, CH | 1 |
| Ho, CM | 1 |
| Lin, PC | 1 |
| Ho, MW | 1 |
| Wang, JH | 1 |
| Kaur, R | 1 |
| Rawat, D | 1 |
| Kakkar, M | 1 |
| Monga, R | 1 |
| Sharma, VK | 1 |
| Brouwer, AE | 2 |
| Rajanuwong, A | 1 |
| Chierakul, W | 1 |
| Griffin, GE | 1 |
| Larsen, RA | 6 |
| White, NJ | 1 |
| Azran, MS | 1 |
| Waljee, A | 1 |
| Biousse, V | 1 |
| Frankel, M | 1 |
| Newman, NJ | 1 |
| Martínez-Baltanás, A | 1 |
| Cuadrado, JM | 1 |
| Jover, F | 1 |
| Roig, P | 1 |
| Woodworth, GF | 1 |
| McGirt, MJ | 1 |
| Williams, MA | 1 |
| Rigamonti, D | 1 |
| Darder, M | 1 |
| Nachega, JB | 1 |
| Rombaux, P | 1 |
| Weynand, B | 1 |
| Thomas, G | 1 |
| Zech, F | 1 |
| Macsween, KF | 1 |
| Marsh, H | 1 |
| Macallan, DC | 1 |
| Powderly, WG | 4 |
| Dannaoui, E | 1 |
| Abdul, M | 1 |
| Arpin, M | 1 |
| Michel-Nguyen, A | 1 |
| Piens, MA | 1 |
| Favel, A | 1 |
| de Souza, JA | 1 |
| Danko, JR | 1 |
| Roberts, A | 1 |
| Mathoulin-Pélissier, S | 1 |
| Launay, O | 1 |
| Thakur, K | 1 |
| Singh, G | 1 |
| Agarwal, S | 1 |
| Rani, L | 1 |
| Milefchik, E | 1 |
| Leal, MA | 4 |
| Haubrich, R | 1 |
| Bozzette, SA | 2 |
| Tilles, JG | 2 |
| Leedom, JM | 3 |
| McCutchan, JA | 2 |
| Brouwer, A | 1 |
| Harrison, T | 1 |
| Busch, M | 1 |
| Weiler, H | 1 |
| Frühmorgen, P | 1 |
| Rühl, U | 1 |
| Roos, W | 1 |
| Schmidt-Westhausen, A | 1 |
| Grünewald, T | 1 |
| Reichart, PA | 1 |
| Pohle, HD | 1 |
| Barbaro, G | 2 |
| Barbarini, G | 2 |
| Di Lorenzo, G | 2 |
| Law, D | 1 |
| Moore, CB | 1 |
| Wardle, HM | 1 |
| Ganguli, LA | 1 |
| Keaney, MG | 1 |
| Dismukes, WE | 2 |
| McCullough, M | 1 |
| Ross, B | 1 |
| Reade, P | 1 |
| Mitchell, DH | 1 |
| Sorrell, TC | 1 |
| Allworth, AM | 1 |
| Heath, CH | 1 |
| McGregor, AR | 1 |
| Papanaoum, K | 1 |
| Richards, MJ | 1 |
| Gottlieb, T | 1 |
| Jones, BE | 1 |
| Haghighat, D | 1 |
| Forthal, D | 1 |
| Bauer, M | 2 |
| Leake, HA | 1 |
| Appleyard, MN | 1 |
| Hartley, JP | 1 |
| Graybill, JR | 4 |
| St Georgiev, V | 1 |
| Hunt, SJ | 1 |
| Reed, SL | 1 |
| Mathews, WC | 1 |
| Torian, B | 1 |
| Finazzi, R | 1 |
| Guffanti, M | 1 |
| Cernuschi, M | 1 |
| Erembourg, L | 1 |
| Capasso, G | 1 |
| Ossi, C | 1 |
| Gesu, G | 1 |
| Witt, MD | 1 |
| Lewis, RJ | 1 |
| Milefchik, EN | 1 |
| Haubrich, RH | 1 |
| Richie, JA | 1 |
| Edwards, JE | 1 |
| Ghannoum, MA | 1 |
| Riantawan, P | 1 |
| Ponglertnapakorn, P | 1 |
| Tebbe, B | 1 |
| Boyvat, A | 1 |
| Geilen, CC | 1 |
| Wölfer, LU | 1 |
| Seibold, M | 1 |
| Orfanos, CE | 1 |
| Aberg, JA | 1 |
| Saag, MS | 1 |
| Cloud, GA | 1 |
| Hamill, RJ | 1 |
| Sobel, JD | 1 |
| Johnson, PC | 1 |
| Tuazon, CU | 1 |
| Kerkering, T | 1 |
| Moskovitz, BL | 1 |
| Chotmongkol, V | 1 |
| Sukeepaisarncharoen, W | 1 |
| Thavornpitak, Y | 1 |
| Casado, JL | 1 |
| Quereda, C | 1 |
| Oliva, J | 1 |
| Navas, E | 1 |
| Moreno, A | 1 |
| Pintado, V | 1 |
| Cobo, J | 1 |
| Corral, I | 1 |
| Zingman, BS | 1 |
| Parisi, A | 1 |
| Malfitano, A | 1 |
| Bruno, R | 1 |
| Calderon, W | 1 |
| Sacchi, P | 1 |
| Patruno, SF | 1 |
| Filice, G | 1 |
| Mayanja-Kizza, H | 1 |
| Oishi, K | 1 |
| Mitarai, S | 1 |
| Yamashita, H | 1 |
| Nalongo, K | 1 |
| Watanabe, K | 1 |
| Izumi, T | 1 |
| Augustine, K | 1 |
| Mugerwa, R | 1 |
| Nagatake, T | 1 |
| Matsumoto, K | 1 |
| Ellepola, AN | 3 |
| Samaranayake, LP | 3 |
| Pfaller, MA | 1 |
| Messer, SA | 1 |
| Gee, S | 1 |
| Joly, S | 1 |
| Pujol, C | 1 |
| Sullivan, DJ | 1 |
| Coleman, DC | 1 |
| Soll, DR | 1 |
| Robinson, PA | 1 |
| Evans, SG | 1 |
| Holtom, PD | 1 |
| Diamond, DA | 1 |
| Coccia, L | 1 |
| Calista, D | 1 |
| Boschini, A | 1 |
| Kordossis, T | 1 |
| Avlami, A | 1 |
| Velegraki, A | 1 |
| Stefanou, I | 1 |
| Georgakopoulos, G | 1 |
| Papalambrou, C | 1 |
| Legakis, NJ | 1 |
| Alonso, M | 1 |
| García, F | 1 |
| Mallolas, J | 1 |
| Soriano, A | 1 |
| Ortega, M | 1 |
| Miró, JM | 1 |
| Gatell, JM | 1 |
| Soriano, E | 1 |
| de Pauw, BE | 1 |
| Meunier, F | 1 |
| Pintado García, V | 1 |
| Martín Dávila, P | 1 |
| Muñoz Labián, V | 1 |
| Quereda Rodríguez-Navarro, C | 1 |
| Sobel, J | 1 |
| Saag, M | 1 |
| Powderly, W | 1 |
| Cloud, G | 1 |
| Riser, L | 1 |
| Hamill, R | 1 |
| Dismukes, W | 1 |
| Chen, YC | 1 |
| Chang, SC | 1 |
| Shih, CC | 1 |
| Hung, CC | 1 |
| Luhbd, KT | 1 |
| Pan, YS | 1 |
| Hsieh, WC | 1 |
| Govender, S | 1 |
| Mutasa, E | 1 |
| Parbhoo, AH | 1 |
| Rollot, F | 1 |
| Bossi, P | 1 |
| Tubiana, R | 1 |
| Caumes, E | 1 |
| Zeller, V | 1 |
| Katlama, C | 1 |
| Bricaire, F | 1 |
| Anil, S | 1 |
| Friese, G | 1 |
| Discher, T | 1 |
| Füssle, R | 1 |
| Schmalreck, A | 1 |
| Lohmeyer, J | 1 |
| Woldeamanuel, Y | 1 |
| Abate, D | 1 |
| Rambeloarisoa, J | 1 |
| Batisse, D | 1 |
| Thiebaut, JB | 1 |
| Mikol, J | 1 |
| Mrejen, S | 1 |
| Karmochkine, M | 1 |
| Kazatchkine, MD | 1 |
| Weiss, L | 1 |
| Piketty, C | 1 |
| Mocsny, N | 1 |
| Kaminski, ZC | 1 |
| Kapila, R | 1 |
| Sharer, LR | 1 |
| Kloser, P | 1 |
| Kaufman, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
| A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.[NCT00002113] | 64 participants | Interventional | Completed | ||||
| A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis[NCT00000639] | 400 participants | Interventional | Completed | ||||
| PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection[NCT00388167] | 320 participants (Anticipated) | Observational | 2004-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for flucytosine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Efficacy of induction regimens for cryptococcal meningitis in HIV-infected adults: a systematic review and network meta-analysis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Deoxycholic Acid; Drug Com | 2021 |
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.
Topics: Africa; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Asia; Fluconazole; | 2013 |
Cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; | 2004 |
Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid | 2005 |
Management of cryptococcosis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Cryptococcosis; Flucytosine; Humans; Lung Dis | 1993 |
Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antigens, Fungal; Cryptococcus n | 1995 |
Treatment of invasive aspergillosis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Aspergillosis; Cholesterol Esters; Drug Carri | 1994 |
Treatment of systemic mycoses in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Azoles; Flucytosine; Humans; Mycoses; Poly | 1993 |
Opportunistic/nosocomial infections. Treatment and developmental therapeutics. II. Cryptococcosis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Azoles; Cross Infection; Cryptococcosis; D | 1993 |
Cryptococcosis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Azoles; Clinical Trials as | 1997 |
Candidal meningitis in HIV-infected patients: analysis of 14 cases.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candidiasis; Female | 1997 |
[Treatment of cryptococcosis in patients with acquired immunodeficiency syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antifungal Agents; Clinical T | 1995 |
The challenge of invasive fungal infection.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis | 1999 |
[The efficacy of sequential treatment with amphotericin B-fluorocytosine and fluconazole in cryptococcal meningitis not associated with AIDS].
Topics: Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combin | 1999 |
Current approach to the acute management of cryptococcal infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Cryp | 2000 |
[Cryptococcosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Child; Cryptococcos | 2001 |
Oral candidal infections and antimycotics.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Infective Agents, Local; Antifungal Agen | 2000 |
Cryptococcal meningitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Drug Therapy, Combination; Fluconazole; Flucy | 1992 |
17 trials available for flucytosine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Topics: Administration, Oral; Africa South of the Sahara; AIDS-Related Opportunistic Infections; Amphoterici | 2022 |
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.
Topics: Administration, Oral; Adult; Africa; AIDS-Related Opportunistic Infections; Amphotericin B; Antifung | 2018 |
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.
Topics: Administration, Oral; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Cerebro | 2010 |
Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiviral Agents; C | 2012 |
A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; AIDS-Related Opportunistic In | 2012 |
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antigens, Fungal; C | 2004 |
Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cohort Studie | 2008 |
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anemia; Antifungal Agents; Cerebrospin | 2008 |
Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; | 1995 |
Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Cerebrospinal Fluid; Cryptococcus neoformans; Drug The | 1994 |
Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis; | 1996 |
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Double-Blind | 1997 |
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Double-Blind | 1997 |
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Double-Blind | 1997 |
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Double-Blind | 1997 |
Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Chi-Squ | 1997 |
Efficacy of a short-term amphotericin B + flucytosine combination therapy followed by itraconazole monotherapy in acute and chronic AIDS-associated cryptococcosis.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antigens, F | 1997 |
Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Drug Therapy, Combination; Female; | 1998 |
Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid; Flucy | 2000 |
Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiretroviral Ther | 2001 |
54 other studies available for flucytosine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa.
Topics: Africa; AIDS-Related Opportunistic Infections; Antifungal Agents; Drug Therapy, Combination; Flucona | 2022 |
An AIDS patient with urine retention.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; China; Cryptococcosis; Cryptococcus neofor | 2019 |
Ending deaths from HIV-related cryptococcal meningitis by 2030.
Topics: Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Ag | 2021 |
Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Brazil; Child | 2018 |
Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Brain Ischemia; Cryptococcus neofor | 2018 |
Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Dru | 2013 |
In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid; Cross | 2012 |
Treating cryptococcal meningitis in people with HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; | 2013 |
Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococc | 2014 |
Access to flucytosine for HIV-infected patients with cryptococcal meningitis – an urgent need.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Flucytosine; Health Services Accessibility | 2014 |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Argentina; Cryptococcosis; | 2016 |
Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cost-Benefit Analysis; Deo | 2016 |
Oral Candida isolates among HIV-infected subjects in Nigeria.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Cand | 2011 |
Responding to the evidence for improved treatment for cryptococcal meningitis in resource-limited settings.
Topics: Africa South of the Sahara; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents | 2012 |
Different presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antigens, Fun | 2012 |
Cryptococcal meningitis in pediatric AIDS.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Child; Drug Therapy, Combi | 2003 |
Episodic third nerve palsy with cryptococcal meningitis.
Topics: Abducens Nerve; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Fat | 2005 |
[Meningeal cryptococcosis as a sign of immune reconstitution syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; An | 2005 |
The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Dr | 2005 |
Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Disease Susceptibility; Fl | 2005 |
Successful treatment of Acanthamoeba rhinosinusitis in a patient with AIDS.
Topics: Acanthamoeba; Adult; AIDS-Related Opportunistic Infections; Amebiasis; Amebicides; Amphotericin B; A | 2005 |
Antifungal treatment for cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Administration Schedu | 2006 |
Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococc | 2006 |
Molluscum or a mimic?
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiretroviral Ther | 2006 |
Images in HIV/AIDS. Pruritic cryptococcal skin lesions in an HIV-positive person.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Dia | 2006 |
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cry | 2007 |
Meningitis caused by Rhodotorula rubra in an human immunodeficiency virus infected patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid | 2007 |
[Paranasal sinus mycetoma with orbital involvement in a patient with AIDS].
Topics: Abscess; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillo | 1995 |
Oral cryptococcosis in a patient with AIDS. A case report.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Cryptococcosis; Dental Care for Chronically I | 1995 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
High prevalence of antifungal resistance in Candida spp. from patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Candida; Drug Resistance, Microbial; Fluconaz | 1994 |
Characterization of genetically distinct subgroup of Candida albicans strains isolated from oral cavities of patients infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Base Sequence; Candida albicans; Candidiasis, Oral; Cell Adhe | 1995 |
Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Drug Resistance, Microbial; Fat Emulsi | 1994 |
Cutaneous Acanthamoeba infection in the acquired immunodeficiency syndrome: response to multidrug therapy.
Topics: Acanthamoeba; Adult; AIDS-Related Opportunistic Infections; Amebiasis; Amebicides; Amphotericin B; A | 1995 |
Unusual presentation of cryptococcosis in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; An | 1996 |
Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Clinical Trials as Topic; Cryptococ | 1996 |
Clinical efficacy of itraconazole with initial flucytosine in AIDS-related cryptococcal meningitis: a preliminary study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Drug Therapy, Combination; Female; | 1996 |
[Clinical fluconazole and itraconazole resistance of oro-gastrointestinal candidiasis in a patient with AIDS].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida albicans; C | 1996 |
[Focusing on therapy of systemic mycoses].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candidiasis; Dose-Response | 1995 |
Treatment of cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; | 1997 |
Treatment of cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Cerebrospinal Fluid; Cryptococcus neoforma | 1997 |
The effect of limited exposure to antifungal agents on the germ tube formation of oral Candida albicans.
Topics: Adhesiveness; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida albi | 1998 |
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Can | 1999 |
Early mycological treatment failure in AIDS-associated cryptococcal meningitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid | 1999 |
Eyelid nodule: a sentinel lesion of disseminated cryptococcosis in a patient with acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cry | 1999 |
First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cry | 1998 |
[Disseminated cryptococcosis in patients with AIDS. Prognostic factors of poor outcome].
Topics: Acute Disease; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Analy | 1999 |
Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; C | 2000 |
Cryptococcal osteomyelitis of the spine.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agent | 1999 |
Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candida albicans; | 2001 |
Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Chorioretinitis; Cr | 2001 |
Characterization of Candida albicans isolates from the oral cavity of HIV-positive patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Candida albicans; Candidiasis, Oral; Case-Control Stud | 1998 |
Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; An | 2002 |
Meningitis due to Prototheca wickerhamii in a patient with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Cerebrospinal Fluid; Cryptococcosis; C | 1992 |